Modulation of immune checkpoint molecule expression in mantle cell lymphoma
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Mantle cell lymphoma (MCL) is an aggressive B-cell malignancy for which novel therapeutics with improved efficacy are greatly needed. To provide support for clinical immune checkpoint blockade, we comprehensively evaluated the expression of therapeutically targetable immune checkpoint molecules on primary MCL cells. MCL cells showed constitutive expression of Programmed Death 1 (PD-1) and Programmed Death Ligand 1 (PD-L1), variable CD200, absent PD-L2, Lymphocyte Activation Gene 3 (LAG-3), and Cytotoxic T-cell Associated Protein 4 (CTLA-4). Effector cells from MCL patients expressed PD-1. Co-culture of MCL cells with T-cells induced PD-L1 surface expression, a phenomenon regulated by IFNγ and CD40:CD40L interaction. Induction of PD-L1 was attenuated by concurrent treatment with ibrutinib or duvelisib, suggesting BTK and PI3K are important mediators of PD-L1 expression. Overall, our data provide further insight into the expression of checkpoint molecules in MCL and support the use of PD-L1 blocking antibodies in MCL patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“dual PI3K d /PI3K g inhibition with duvelisib limits PD-L1 expression by lymphoma cells (Harrington et al., 2019)”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Harrington et al., 2019
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860 · cited 1×
“to the endogenous control gene CD52 [25] and calculated by the 2 (DDCt) method [26].”
MethodPD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198 · cited 1×
“Though therapeutic strategies with these inhibitors are still being optimized, the presence or absence of specific immune checkpoints on the surface of cancer cells and effector cells appears to play a critical role as a biomarker of response to therapy [19,33,34].”
BackgroundThe phosphoinositide 3-kinase pathway
Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621 · cited 1×
“This may be related to the fact that PI3K is downstream of many growth factor receptors, in comparison with BTK, which is more specific for BCR signaling [40,41].”
BackgroundFreeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Mutation of the mouse klotho gene leads to a syndrome resembling ageing
Kuro-o, M., Matsumura, Y., Aizawa, H., Kawaguchi, H., Suga, T., Utsugi, T., Ohyama, Y., Kurabayashi, M., Kaname, T., Kume, E., et al. (1997) · Nature · doi:10.1038/36285 · Cited by 3,837
Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749
Research works printed but not linked: 1
- Winter D,. C f J Using the Student’s “t”-test with extremely small sample sizes. Pract. Assess Res Eval. 2013; 18: 1– 12.
Cited by
Immunomodulation by targeted anticancer agents
Petroni, G., Buqué, A., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.009 · Cited by 212
Immune checkpoint inhibitors in lymphoma: challenges and opportunities
Hatic, H., Sampat, D., & Goyal, G. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-6833 · Cited by 72
“CTLA-4 works by indirectly diminishing signaling through its co-stimulatory receptor, CD28 (Figure 1).”
BackgroundInfluentialImmune-Checkpoint Inhibitors in B-Cell Lymphoma
Armengol, M., Santos, J. C., Fernández-Serrano, M., Profitós-Pelejà, N., Ribeiro, M. L., & Roué, G. (2021) · Cancers · doi:10.3390/cancers13020214 · Cited by 65
“Several studies have shown that PD-L1 expression is low or absent in MCL [65,90], whereas others have shown a variable but constitutive expression of PD-L1 on tumour cells in both cell lines and primary patient samples [34].”
BackgroundMulder, T. A., Wahlin, B. E., Österborg, A., & Palma, M. (2019) · Cancers · doi:10.3390/cancers11070915 · Cited by 45
Yang, X., Cao, Z., Wu, P., & Li, Z. (2019) · Medical Science Monitor · doi:10.12659/msm.916950 · Cited by 29
“The same size wounds were prepared in the same part of the control group and the ibrutinib group [17].”
BackgroundMethod
Metadata
- Authors
- Harrington, B. K., Wheeler, E., Hornbuckle, K., Shana’ah, A. Y., Youssef, Y., Smith, L., Hassan II, Q., Klamer, B., Zhang, X., Long, M., Baiocchi, R. A., Maddocks, K., Johnson, A. J., Byrd, J. C., & Alinari, L.
- Affiliations
- Michigan State University (US)
- The Ohio State University (US)
- Medical Scientist Training Program, The Ohio State University, Columbus, OH, USA;
- Janssen Biotech Inc., Horsham, PA, USA
- Corresponding author
- Alinari, Lapo
- ORCID
- Venue
- Leukemia & Lymphoma
- Publisher
- Informa UK Limited
- Published
- 2019-03-01
- Volume
- 60
- Issue
- 10
- Pages
- 2498-2507
- ISSN
- 1026-8022 (ISSN-L)
- 1042-8194
- 1029-2403
- PMC
- PMC6773518
- OpenAlex
- W2918733328
- Cited by
- 31
- References
- 48
- Citations by year
- 2025: 4 · 2024: 4 · 2023: 3 · 2022: 7 · 2021: 5 · 2020: 6 · 2019: 2
- FWCI
- 3.67
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Leukemia & lymphoma/Leukemia and lymphoma (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- NIH NCI (T32CA009338)
- CLL Research Consortium (P01 CA081534)
- OSU Comprehensive Cancer Center (P30 CA016058)
- Pelotonia Graduate Fellowship
- CCTS Davis-Bremer Scholar Award
- D. Warren Brown Foundation
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- mantle cell lymphoma, immune checkpoint molecules, PD-1, PD-L1, CD200, PD-L2, LAG-3, CTLA-4, T cell co-culture, interferon-gamma, CD40-CD40L interaction, ibrutinib, duvelisib, BTK inhibition, PI3K inhibition, PD-L1 blockade, B-cell malignancies
- MeSH terms
- Humans, Receptors, Antigen, B-Cell, Transcription, Genetic, Biomarkers, Tumor, Signal Transduction, Gene Expression Regulation, Neoplastic, T-Lymphocyte Subsets, Lymphoma, Mantle-Cell, B7-H1 Antigen, CTLA-4 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Modulation of immune checkpoint molecule expression in mantle cell lymphoma. https://app.cochat.ai/papers/10.1080/10428194.2019.1569231
- The paper
- Harrington, B. K., Wheeler, E., Hornbuckle, K., Shana’ah, A. Y., Youssef, Y., Smith, L., Hassan II, Q., Klamer, B., Zhang, X., Long, M., Baiocchi, R. A., Maddocks, K., Johnson, A. J., Byrd, J. C., & Alinari, L. (2019). Modulation of immune checkpoint molecule expression in mantle cell lymphoma. Leukemia & Lymphoma. https://doi.org/10.1080/10428194.2019.1569231
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.